CD8A and breast cancer: Based on the correlation analysis between KRT19P3 and PD-L1, CD8+ T, it was hypothesized that KRT19P3 may inhibit BC progression by reducing PD-L1 expression in tumor cells and activating the tumor-killing potential of CD8+ T cells, which is also consistent with the findings of Sun et al.